EPZM Technical Analysis 🧙Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
EPZM
EPZM Technical Analysis 🧙Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
EPZM - 110% RISE- ASSET ON STRONG LEVEL OF DEMAND
- STRONG PRODUCT LAUNCH
- GOOD CASH AT BANK TO SUPPORT NEW PRODUCT GROWTH AND MARKETING STRATEGIES.
- NET PROFIT MARGINS IMPROVED OVER THE LAST 3 QTRS.
- ASSET SHOULD SEE IMPROVED EARNINGS INTO 2021
GOOD RR.
EPZM High Frequency Trader Buying FrenzyEPZM ran quickly out of a very short-term bottom with High Frequency Trader action. High Frequency Trader algos are focused on 3 major industries at this time. This is creating opportunities for retail Swing and Day Traders who can enter with the Professional Traders, who are setting up for the High Frequency Trader algo triggers.
EPZM - DAILY CHART Hi, today we are going to talk about Epizyme and its current landscape.
Epizyme is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company received unanimous approval from the FDA for its cancer drug Tazemetostat for the treatment of patients with epithelioid sarcoma. Amid the simmering of the Cancer Drug Race, with the sector hitting $5.2 billion in M&A deals, putting this news for Epizyme at a higher level for the company and push its shares to a higher level.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NASDAQ: #Epizyme | $EPZM looks like an EASY SHORT! NASDAQ: #Epizyme | $EPZM looks like an EASY SHORT! All 5 waves appear to be in! Expect a BIG PULLBACK come Monday!
